运动障碍
左旋多巴
医学
帕金森病
疾病
临床试验
不利影响
药理学
内科学
作者
Jawad Al-Kassmy,Christine Sun,Philippe Huot
出处
期刊:Neurodegenerative disease management
[Future Medicine]
日期:2023-04-01
卷期号:13 (2): 101-112
标识
DOI:10.2217/nmt-2022-0039
摘要
Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT 1A ) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT 1A agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT 1A agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.
科研通智能强力驱动
Strongly Powered by AbleSci AI